It was found that sorafenib induces necroptosis in HCC, while HSP90α can block resistance to sorafenib under hypoxic conditions, and in combination with its inhibitor, 17-AAG, is a potential regimen suitable for the treatment of HCC45. The gene discussed is HSP90AA1; the disease is hepatocellular carcinoma.